Search Results

You are looking at 61 - 70 of 438 items for :

Clear All
Full access

Agnes Smaradottir, Angela L. Smith, Andrew J. Borgert and Kurt R. Oettel

mentioned fatigue most often as a significant barrier to exercise (50%). Other barriers included symptoms of disease, such as dyspnea, pain, and impaired mobility. Side effects of treatment, including nausea, vomiting, diarrhea, neuropathic pain, emotional

Full access

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry and Kristin L. Campbell

survival. 1 Proposed mechanisms for this positive effect on chemotherapy treatment tolerance include exercise-related amelioration of specific symptoms or toxicities that cause treatment reductions or delays, including neutropenia, fatigue, and neuropathy

Full access

Paul F. Engstrom

I am pleased to work with the editor-in-chief of JNCCN, Hal Burstein, MD, PhD, in organizing this issue of the journal dedicated to colon and rectum cancer management, and I appreciate the opportunity to note some of the updates to the field in the past year. In 2009, the NCCN Clinical Practice Guidelines in Oncology were expanded to include a survivorship component. Long-term follow-up care of colorectal cancer survivors should include management of late complications and encouraging patients to modify their lifestyle through improved exercise and diet. Another major change in the guidelines represented the determination of tumor KRAS gene status before starting treatment with an epidermal growth factor receptor (EGFR) inhibitor, such as cetuximab or panitumumab. Data included in the guidelines show that patients whose tumor expresses KRAS mutation have little or no likelihood of responding to the EGFR inhibitors. The edition of the guidelines published in this issue also emphasizes the use of systemic combination chemotherapy such as FOLFOX or FOLFIRI with or without bevacizumab in the attempt to reduce the size of colorectal metastasis as well as the primary tumor and to allow patients with initially unresectable disease to be candidates for resection. These changes in the guidelines are reflected and expanded in the authored manuscripts. For example, Denlinger and Barsevick review the literature on colorectal cancer survivorship. They note clear evidence that quality of life is diminished when treatment-related symptoms, such as fatigue, distress, and sleep difficulties) plague colorectal cancer survivors. The long-term effects of treatment,...
Full access

Pancreas Cancer Izeradjene Kamel PhD Hingorani Sunil R. MD, PhD 11 2007 5 5 10 10 1042 1042 1053 1053 0051042 10.6004/jnccn.2007.0087 Cancer-Related Fatigue 11 2007 5 5 10 10 1054 1054 1054 1054 0051054 10.6004/jnccn.2007.0088 Update

Full access

Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre and James Rosberg

. Factors influencing quality of life in cancer patents: anemia and fatigue . Semin Oncol 1998 ; 25 : 43 – 46 . 4 Curt GA . Impact of fatigue on quality of life in oncology patients . Semin Hematol 2000 ; 37 : 14 – 17 . 5 Sobrero

Full access

Lindsey A. Kluck and Ronald S. Go

Re: Sriram Yennurajalingam, Nizar M. Tannir, Janet L. Williams, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients with Advanced Cancer. J Natl Compr Canc Netw 2017

Full access

.2010.0066 Cancer-Related Fatigue Berger Ann M. PhD, RN, AOCN Abernethy Amy Pickar MD Atkinson Ashley RN, MSN, OCN Barsevick Andrea M. PhD, RN AOCN Breitbart William S. MD Cella David PhD Cimprich Bernadine PhD

Full access

Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat and Qian Zhang

.11) Figure 1 . Paobinostat had a significantly lower risk of lymphopenia (OR 0.25 95% CI 0.15-0.42, p=<0.0001) Panobinostat was however, associated with two times more risk of anemia (OR 2.82 95% CI 1.82-4.38, p=<0.0001), fatigue (OR 2.36 95% CI 1.64-3.38, p

Full access

Daniel Shasha, Pierre Cremieux and Louis Harrison

patients undergoing radiation therapy . Semin Oncol 2001 ; 28 ( suppl 8 ): 54 – 59 . 4 Irvine D Vincent L Graydon JE . The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy: A comparison

Full access

1 1 3 3 The Compleat Oncologist Winn Rodger J. MD 7 2003 1 1 3 3 303 303 303 303 10.6004/jnccn.2003.0028 Cancer-Related Fatigue Clinical Practice Guidelines in Oncology 7 2003 1 1 3 3 308 308 308 308 10.6004/jnccn.2003.0029 A